|
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical research trials and Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer  Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
For Condition: Thyroid Cancer,Renal Cell Cancer,Kidney Cancer,Lung Cancer,Melanoma,Eye Cancer,Head and Neck Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Yale Cancer Center
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.
Details: OBJECTIVES: I. Determine the maximum tolerated dose (MTD), toxic effects, and the preliminary antitumor activity of indium In 111 pentetreotide. PROTOCOL OUTLINE: This is a dose escalation study. Patients receive indium In III pentetreotide (OctreoScan) IV on day 1. Imaging is conducted on days 3 and 6. Treatment continues weekly for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of at least 3 patients receive escalating doses of OctreoScan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicities. Patients are followed every 3 months for the first year, then every 6 months thereafter. PROJECTED ACCRUAL: Up to 35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven malignancy with no alternate treatments available - Measurable or evaluable progressive disease - Somatostatin receptors present on tumor and uptake demonstrated on diagnostic scan with OctreoScan --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - Endocrine therapy: Not specified - Radiotherapy: At least 4 weeks since prior wide field radiation therapy - Surgery: Recovery from prior surgery --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 3 months - Hematopoietic: Platelet count at least 100,000/mm3; Absolute neutrophil count at least 1,500/mm3 - Hepatic: Total bilirubin no greater than 2.0 mg/dL - Renal: Creatinine clearance at least 40 mL/min - Other: No active infections; Not HIV positive; No coexisting medical condition; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JohnMurren, Study Chair, Yale Cancer Center
Yale Comprehensive Cancer Center
New Haven, Connecticut, 06520-8028
United States
Additional Information:
Study ID Numbers: CDR0000065414; YALE-HIC-9041,NCI-G97-1154
Study Start Date: July 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002947
Other Melanoma Studies:
1. Fludarabine, Total-body Irradiation, Donor Peripheral Stem Cell Transplantation, and Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
2. Gene Therapy in Treating Patients With Cancer
3. Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
4. Phase I Study of SU006668 in Patients With Advanced Solid Tumors
5. Phase I/II Open Label Multi-Center Study of CpG 7909 in Patients with Stage IV Renal Cell Cancer
Related Studies:
Other Melanoma Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
|
|
|
|
|
|
|
